{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:10:18Z","timestamp":1778170218170,"version":"3.51.4"},"reference-count":75,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Vaccines are the first line of defense against coronavirus disease 2019 (Covid\u201019). However, the antiviral drugs provide a new tool to fight the Covid\u201019 pandemic. Here we aimed for a comparative evaluation of authorized drugs for treating Covid\u201019 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched in PubMed and Google Scholar using keywords and terms such as Covid, SARS\u2010CoV\u20102, Coronavirus disease 2019, therapeutic management, hospitalized Covid\u201019 patients, Covid\u201019 treatment. We also gathered information from reputed newspapers, web portals, and websites. We thoroughly observed, screened, and included the studies relevant to our inclusion criteria. We included only the United States Food and Drug Administration (FDA) authorized drugs for this review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that molnupiravir and paxlovid are available for oral use, and remdesivir is for only hospitalized patients. Paxlovid is a combination of nirmatrelvir and ritonavir, nirmatrelvir is a protease inhibitor (ritonavir increases the concentration of nirmatrelvir), and the other two (remdesivir and molnupiravir) are nucleoside analog prodrugs. Remdesivir and molnupiravir doses do not need to adjust in renal and hepatic impairment. However, the paxlovid dose adjustment is required for mild to moderate renal or hepatic impaired patients. Also, the drug is not allowed for Covid\u201019 patients with severe renal or hepatic impairment. Preliminary studies showed oral antiviral drugs significantly reduce hospitalization or death among mild to severe patients. Moreover, the US FDA has approved four monoclonal antibodies for Covid\u201019 treatment. Studies suggest that these drugs would reduce the risk of hospitalization or severity of symptoms. World Health Organization strongly recommended the use of corticosteroids along with other antiviral drugs for severe or critically hospitalized patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>All authorized drugs are effective in inhibiting viral replication for most SARS\u2010CoV\u20102 variants. Therefore, along with vaccines, these drugs might potentially aid in fighting the Covid\u201019 pandemic.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hsr2.671","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T06:05:16Z","timestamp":1655186716000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Comparative evaluation of authorized drugs for treating Covid\u201019 patients"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8402-0740","authenticated-orcid":false,"given":"Towhidul","family":"Islam","sequence":"first","affiliation":[{"name":"Department of Pharmacy University of Asia Pacific Dhaka Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moynul","family":"Hasan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Jagannath University Dhaka Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Saydur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Jagannath University Dhaka Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2820-3144","authenticated-orcid":false,"given":"Md. Rabiul","family":"Islam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Asia Pacific Dhaka Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.545"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255379"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/00368504211058562"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/20587384211065628"},{"key":"e_1_2_12_6_1","first-page":"1823","article-title":"Recommendation and roadmap of mass vaccination against COVID\u201019 pandemic in Bangladesh as a lower\u2010middle\u2010income country (LMIC)","volume":"76","author":"Hossain MJ","year":"2021","journal-title":"Ach\u00a0Razi Inst"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27574"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.05.007"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27019"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00456"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe0751"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26814"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.1c00519"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26264"},{"key":"e_1_2_12_15_1","unstructured":"FDA. FDA approves first treatment for COVID\u201019. FDA news release.\u00a02020.\u00a0Accessed December 25 2021.\u00a0https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19\u200b\u200b\u200b\u200b\u200b\u200b"},{"key":"e_1_2_12_16_1","unstructured":"Gliead. Remdesivir global marketing authorization 1.\u00a02021.\u00a0Accessed December 25 2021.\u00a0https:\/\/www.gilead.com\/purpose\/advancing-global-health\/covid-19\/veklury-global-marketing-authorization\u200b\u200b\u200b\u200b\u200b\u200b"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190021997001"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2021.04.014"},{"key":"e_1_2_12_19_1","unstructured":"FDA. Coronavirus (COVID\u201019) update: FDA authorizes drug combination for treatment of COVID\u201019. FDA news release.\u00a02020. Accessed December 25 2021.\u00a0https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19\u200b\u200b\u200b\u200b\u200b\u200b"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10121477"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01557-7"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-00984-5"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00570-1"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.01537-21"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01155-21"},{"key":"e_1_2_12_27_1","unstructured":"FDA. Coronavirus (COVID\u201019) update: FDA authorizes additional oral antiviral for treatment of COVID\u201019 in certain adults | FDA. FDA news release.\u00a02021.\u00a0Accessed December 26 2021.\u00a0https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain\u200b\u200b\u200b\u200b\u200b"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab361"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00835-2"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00837-4"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27517"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103595"},{"key":"e_1_2_12_34_1","first-page":"\u200b","article-title":"N4\u2010hydroxycytidine and inhibitors of dihydroorotate dehydrogenase synergistically suppress SARS\u2010CoV\u20102 replication","author":"Stegmann KM","journal-title":"bioRxiv"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab247"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2117814"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102329"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26239-2"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179124"},{"key":"e_1_2_12_41_1","unstructured":"FDA. Coronavirus (COVID\u201019) Update: FDA authorizes first oral antiviral for treatment of COVID\u201019 | FDA. FDA news release.\u00a02021.\u00a0Accessed December 26 2021.\u00a0https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008629608556"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02657-X"},{"key":"e_1_2_12_44_1","unstructured":"WoodleyM. RACGP\u2014what is Australia's potential new COVID treatment? NEWSGP. 2021.\u00a0Accessed December 26 2021.\u00a0https:\/\/www1.racgp.org.au\/newsgp\/clinical\/what-is-australia-s-potential-new-covid-treatment\u200b\u200b\u200b\u200b\u200b\u200b"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2713"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.acx9605"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.37201\/req\/158.2021"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27540"},{"key":"e_1_2_12_49_1","first-page":"\u200b","article-title":"Nirmatrelvir\/ritonavir use: managing clinically significant drug\u2010drug interactions with transplant immunosuppressants","author":"Lange NW","journal-title":"Am J Transplant"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1522426"},{"key":"e_1_2_12_51_1","unstructured":"NIH. Anti\u2010SARS\u2010CoV\u20102 monoclonal antibodies | COVID\u201019 treatment guidelines. National Institutes of Health: COVID\u201019 treatment guidelines.2022. Accessed February 4 2022.\u00a0https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/anti-sars-cov-2-antibody-products\/anti-sars-cov-2-monoclonal-antibodies\/"},{"key":"e_1_2_12_52_1","unstructured":"Bamlanivimab\/etesevimab. Public Health Emergency. 2022. Accessed February 4 \u00a02022.https:\/\/www.phe.gov\/emergency\/events\/COVID19\/investigation-MCM\/Bamlanivimab-etesevimab\/Pages\/default.aspx"},{"key":"e_1_2_12_53_1","unstructured":"REGEN\u2010COV. Public Health Emergency. Accessed February 4 \u00a02022.https:\/\/www.phe.gov\/emergency\/events\/COVID19\/investigation-MCM\/cas_imd\/Pages\/default.aspx"},{"key":"e_1_2_12_54_1","unstructured":"CavazzoniP.\u00a0Coronavirus (COVID\u201019) update: FDA limits use of certain monoclonal antibodies to treat COVID\u201019 due to the Omicron variant | FDA. FDA STATEMENT. 2022. Accessed February 4 \u00a02022.https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o97"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2990"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107934"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00751-9"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202576"},{"issue":"12","key":"e_1_2_12_60_1","first-page":"e20620","article-title":"Use of baricitinib in combination with remdesivir and steroid in COVID\u201019 treatment: a multicenter retrospective study","volume":"13","author":"So JM","year":"2021","journal-title":"Cureus"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106749"},{"key":"e_1_2_12_62_1","first-page":"1","article-title":"Baricitinib: two birds with one stone","author":"Saj F","year":"2022","journal-title":"Indian J Hematol Blood Transfus"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031994"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-021-02169-0"},{"key":"e_1_2_12_65_1","unstructured":"Remdesivir and Covid\u201019.\u00a0Accessed April 22 2022\u200b\u200b\u200b\u200b\u200b\u200b.\u00a0https:\/\/clinicaltrials.gov\/ct2\/results?term=remdesivir%2Band%2Bcovid-19"},{"key":"e_1_2_12_66_1","unstructured":"Molnupiravir and Covid\u201019. Accessed April 22 2022.https:\/\/clinicaltrials.gov\/ct2\/results?term=molnupiravir%2Band%2Bcovid-19"},{"key":"e_1_2_12_67_1","unstructured":"PF\u201007321332 and Covid\u201019.\u00a0Accessed April 22 2022.\u00a0https:\/\/clinicaltrials.gov\/ct2\/results?term=PF-07321332%2Band%2Bcovid-19%20"},{"key":"e_1_2_12_68_1","unstructured":"COVID\u201019 treatment guidelines.\u00a0Accessed April 22 2022.\u00a0https:\/\/www.covid19treatmentguidelines.nih.gov\/tables\/mab-data\/"},{"key":"e_1_2_12_69_1","unstructured":"Therapeutic management of hospitalized adults with COVID\u201019.\u00a0Accessed\u00a0April 22 2022.\u00a0https:\/\/www.covid19treatmentguidelines.nih.gov\/management\/clinical-management\/hospitalized-adults--therapeutic-management\/"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1515\/jbcpp-2021-0251"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27503"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27546"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27635"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27633"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1177\/2632010X221075584"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1177\/2632010X221099889"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.671","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.671","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T16:34:36Z","timestamp":1692635676000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1002\/hsr2.671"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.671","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"2022-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e671"}}